[ * * * ] = portions of this exhibit have been omitted and filed separately with the securities and exchange commission. confidential treatment requested under 17 c. f. r. section 240. 24b - 2. exhibit 10. 3 execution version uick oxford biomedica ( uk ) ltd and axovant sciences gmbh licence agreement this licence agreement ( the “ agreement ” ) is made on june 5, 2018 ( the “ effective date ” ) between ( 1 ) oxford biomedica ( uk ) ltd, a company incorporated in england and registered under number 03028927, whose registered office is at windrush court, transport way, ( 1 ) ( 1 ) oxford biomedica ( uk ) ltd, a company incorporated in england and registered under number 03028927, whose registered office is at windrush court, transport way, oxford biomedica ( uk ) ltd, a company incorporated in england and registered under number 03028927, whose registered office is at windrush court, transport way, oxford, ox4 6lt ( “ biomedica ” ) ; and ( 2 ) axovant sciences gmbh, a company organized and existing under the laws of switzerland, having its principal place of business at viaduktstrasse 8, 4051 basel, switzerland ( the “ licensee ” ). ( 2 ) ( 2 ) axovant sciences gmbh, a company organized and existing under the laws of switzerland, having its principal place of business at viaduktstrasse 8, 4051 basel, switzerland ( the “ licensee ” ). axovant sciences gmbh, a company organized and existing under the laws of switzerland, having its principal place of business at viaduktstrasse 8, 4051 basel, switzerland ( the “ licensee ” ). background ( a ) biomedica has special expertise and longstanding experience in the field of lentiviral vector gene therapy products, including pre - clinical and clinical development, manufacture, testing and product release. ( a ) ( a ) biomedica has special expertise and longstanding experience in the field of lentiviral vector gene therapy products, including pre - clinical and clinical development, manufacture, testing and product release. biomedica has special expertise and longstanding experience in the field of lentiviral vector gene therapy products, including pre - clinical and clinical development, manufacture, testing and product release. ( b ) biomedica has developed